Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Gold/Mining/Energy : Nuvo Research Inc -- Ignore unavailable to you. Want to Upgrade?

To: Mark Bartlett who wrote (8674)	2/7/2002 10:29:11 PM
From: Montana Wildhack	Respond to of 14101

Mark, I can't imagine what the not-high-quality submissions might be going through.

To: Mark Bartlett who wrote (8674)	2/7/2002 10:37:16 PM
From: Joe Krupa	Respond to of 14101

Hi Mark, Thanks for that find. That helps the understanding of the process a bit. "The TPD aims not to issue very many NODs (Notice of Deficiency, which stops the review process) but to rely on clarifaxes and NON (does not stop the review process) to address deficiencies in high quality submissions" Given that the NON (Notice of Non-Compliance) is a process in which HC appears to clarify certain points in a NDS, it seems like a perfect process to invoke to buy some time until FDA pronounces. It's almost like somebody at HC started flipping through the NDS process to see which throw back they could pull out of the hat to stall the final decision, just enough to let FDA have the floor first. Again, what a joke! joe